

CarraShield Labs

CarraShield Labs Issued Ground-breaking Patent for Anti-viral Gel Technology Aimed at Preventing HPV Infections

For Immediate Release

Executive Summary

CarraShield Labs, Inc. announced today that Chief Scientist Dr. Mario Tremblay has been issued a U.S. patent for a new gel that is designed as a protective barrier against HPV. The patent cites the formula's anti-viral properties and its ability to be easily applied topically.

September 23, 2020, St Petersburg, Florida – [CarraShield Labs, Inc.](#) is pleased to announce the issuance of [US Patent 10,688,043](#), the first in a series of patent filings developed by its Chief Scientist, Dr. Mario Tremblay, covering the unique, natural, anti-viral gel technology contained in a formulation called CarraShield®. The technology uses a highly unique sea algae extract as the active ingredient, resulting in a product that is not only the first topical gel to show efficacy against human papillomavirus (HPV), but also one that is naturally derived.

As described in the patent, CarraShield technology works as a protective barrier, with no chemical interactions with the body. The barrier mechanism works to reduce transmission from infected individuals by blocking and containing viral shedding.

Referenced in the patent are published independent clinical results from the [CATCH \(Carrageenan-gel Against Transmission of Cervical HPV\)](#) McGill University Medical School Phase IIb study that shows women using the Divine CarraShield active product in the double-blind study had a reduced incident rate of HPV infections as compared to women using a placebo lubricant. Women in the study were asked to use the lubricant they were issued for the study in each sexual encounter for one year.



CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute. The National Cancer Institute's [in vitro](#) and [in vivo](#) studies showed CarraShield Labs' technology to be highly effective in blocking transmission of the human papillomavirus (HPV). This was followed by confirmatory studies at the [Albert Einstein College of Medicine](#) and [joint work with The Population Council](#). The *in vitro* studies also demonstrated the superiority of the patented CarraShield carrageenan versus other carrageenan types, even at low concentrations.



There are approximately 470,000 cases per year of Invasive Cervical Cancer (ICC) globally; comprising 10% of all female cancers and it is the second most prevalent cancer in women after breast cancer. HPV is also strongly linked to penile, vaginal/vulvar and anal cancers as well as being the root cause of genital warts. The detection of oral HPV infection has also increased

significantly in the past 10 years, which is linked to a rising number of cases of oral, neck and throat cancers.

The CarraShield gel technology is the starting point for new ways to help prevent HPV-induced cancers and warts that may prove to supplement vaccines. Current HPV vaccines only protect against up to 9 types of HPV virus out of over 200 HPV types. It is estimated that only 107 million women have been vaccinated out of a global population of 2.8 billion. “**While the HPV vaccine protects against at the most nine strains of the virus, potentially, the carrageenan-based lubricant can provide total protection from HPV,**” stated Dr. Eduardo Franco, Principle Investigator, University of McGill Medical School.

Consumer Notice

This announcement is for the scientific and research community. The testing on anti-viral properties has not been completed and the FDA has not reviewed results. CarraShield Labs does not claim that CarraShield or Divine 9 will prevent, mitigate, or cure any disease or infection.

About CarraShield Labs, Inc.

CarraShield Labs, Inc., combines nature with science to create products that improve well-being and overall health. Intensive research has led to the company's proprietary, naturally derived sea algae concentrate called CarraShield®. The first product to contain CarraShield is Divine 9®, a water-based personal lubricant. For information on technology licensing opportunities, contact the company at <http://www.carrashieldlabs.com>.

#